Mostrar el registro sencillo del ítem

dc.contributor.authorAlarcón-Veleiro, C
dc.contributor.authorLópez-Calvo, I
dc.contributor.authorBerjawi, L
dc.contributor.authorLucio Gallego, Sergio
dc.contributor.authorMato Basalo, Rocío
dc.contributor.authorQuindós Varela, María 
dc.contributor.authorLesta Mellid, Rocío
dc.contributor.authorSantamaría Cainzos, Isabel
dc.contributor.authorVarela-Rodríguez, S
dc.contributor.authorFraga Rodríguez, Máximo Francisco 
dc.contributor.authorQuintela, M
dc.contributor.authorVizoso-Vázquez, A
dc.contributor.authorArufe Gonda, Mº del Carmen
dc.contributor.authorFafián Labora, Juan A
dc.date.accessioned2025-06-23T08:23:56Z
dc.date.available2025-06-23T08:23:56Z
dc.date.issued2025-04-29
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20201
dc.description.abstract[EN] Ferroptosis is a regulated form of cell death characterised by iron-dependent lipid peroxidation, a process intricately linked to cellular redox homeostasis. This form of cell death is induced by the accumulation of intracellular iron and the subsequent generation of reactive oxygen species (ROS), which leads to lipid peroxidation and ultimately cell death. Ferroptosis is distinct from traditional forms of cell death, such as apoptosis, and holds significant therapeutic potential, particularly in cancers harboring rat sarcoma virus (RAS) mutations, such as epithelial ovarian cancer (EOC). EOC is notoriously resistant to conventional therapies and is associated with a poor prognosis. In this review, we examine recent progress in the understanding of ferroptosis, with a particular focus on its redox biology and the complex regulatory networks involved. We also propose a novel classification system for ferroptosis modulators, grouping them into six categories (I, II, III, IV, V and VI) based on their mechanisms of action and their roles in modulating cellular redox status. By refining these categories, we aim to provide deeper insights into the role of ferroptosis in cancer biology, especially in EOC, and to identify potential therapeutic avenues. We propose that further investigation of ferroptosis in the context of redox biology could reveal novel biomarkers and therapeutic targets, offering promising strategies to overcome resistance mechanisms and improve clinical outcomes for patients with EOC and other treatment-resistant cancers.es
dc.language.isoenges
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleFerroptosis: An emerging strategy for managing epithelial ovarian canceres
dc.typeArtigoes
dc.identifier.doi10.1016/j.biopha.2025.118065
dc.identifier.essn1950-6007
dc.identifier.pmid40306179
dc.journal.titleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapiees
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Instituto de Investigación Biomédica de A Coruña (INIBIC)es
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de A Coruña - Complexo Hospitalario Universitario de A Coruñaes
dc.page.initial118065es
dc.rights.accessRightsopenAccesses
dc.subject.keywordCHUACes
dc.subject.keywordINIBICes
dc.typefidesArtigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis)es
dc.typesophosArtículo de Revisiónes
dc.volume.number187es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional